Markus Queisser
@mqueisser.bsky.social
📤 15
📥 31
📝 2
reposted by
Markus Queisser
Peter Kenny
about 1 month ago
Three (3) Sustaining Innovation
#PostDoc
opportunities in fragment-based design at Astex Pharmaceuticals (Cambridge UK) ref: SI/0825 | closing: 30-Sep-2025
#FBD
#FBDD
#SBDD
#MedChem
#ChemBiol
#StructBiol
#ChemPostDoc
#PostDocJobs
#chemsky
đź§Ş
www.cloudonlinerecruitment.co.uk/Astex/Vacanc...
loading . . .
Astex Careers Astex Careers
Astex Pharmaceuticals is a world leader in innovative drug discovery and development. The company has successfully applied its proprietary Fragment-Based Drug Discovery platform to generate multiple new drug candidates that are progressing in clinical development. Successful collaborations have led to three launched oncology drugs (Kisqali® partnered with Novartis, Balversa® partnered with Janssen and Truqap™ partnered with AstraZeneca). Astex continues to grow and focuses on Neurological Disorders and Oncology.
https://www.cloudonlinerecruitment.co.uk/Astex/VacancyDetails.aspx?FromSearch=True&MenuID=&VacancyID=86
0
4
4
reposted by
Markus Queisser
Chris Parker
2 months ago
Excited to share a new preprint from the lab. We show that PTMs like phosphorylation & glycosylation dynamically reshape proteome-wide ligandability in cells, including proteins like KRAS. Great collaboration with the Huang Lab,
@forlilab.bsky.social
and BMS.
www.biorxiv.org/content/10.1...
loading . . .
Post-Translational Modifications Remodel Proteome-Wide Ligandability
Post-translational modifications (PTMs) vastly expand the diversity of human proteome, dynamically reshaping protein activity, interactions, and localization in response to environmental, pharmacologi...
https://www.biorxiv.org/content/10.1101/2025.07.31.667978v1
0
80
25
reposted by
Markus Queisser
Marshall Burke
5 months ago
What happens to science under autocracy? The rise of the National Socialist Party in 1930s Germany provides an (admittedly extreme) example. Prior to the early 1930s, scientists at German institutions won a third of Nobels. 10 years later, that number was 5%, and has never recovered.
13
522
295
reposted by
Markus Queisser
Women in TPD & Induced Proximity
8 months ago
An important safety manuscript for all working with CRBN binders or recruiters! Congratulations Lise Loberg at AbbVie and Katie Stamp at BMS for leading this cross-industry collaboration effort and all other contributors!
www.sciencedirect.com/science/arti...
loading . . .
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider
Targeted protein degraders (or degraders) are an emerging small molecule drug modality with transformative therapeutic potential. Currently, most degr…
https://www.sciencedirect.com/science/article/abs/pii/S0273230025000236
0
1
1
reposted by
Markus Queisser
Ingo Hartung
8 months ago
Small molecular weight drug molecules are products of design. Multiple characteristics are designed into one chemical structure. Read about how the combination of experimental data with calculated properties streamlines the discovery of oral designer PROTACs:
pubs.rsc.org/en/content/a...
@rsc.org
0
6
2
reposted by
Markus Queisser
Chemjobber
8 months ago
This_one_goes_to_eleven dot gif
add a skeleton here at some point
0
15
2
Wonderful Molecular Glue Summit in Boston. Key Learning: there are Molecular Glue Degrader (MGD), Competitive Molecular Glues (CMG), Allosteric Molecualr Glues (AMG) and Intramolecular Glues (IMG) - you just have to look for them !
9 months ago
0
0
0
reposted by
Markus Queisser
Keith Hornberger
over 1 year ago
If we were good at “validating” targets, the clinical trial failure rate likely wouldn’t be what it is. It’s an argument for large investment in basic disease biology and better model systems. No tech that churns out more compounds against the wrong target is gonna fix that. 15/
1
18
5
reposted by
Markus Queisser
Derek Lowe
almost 2 years ago
I liked that one!
loading . . .
A Rather Unwelcoming Degrader Enzyme
https://www.science.org/content/blog-post/rather-unwelcoming-degrader-enzyme
1
2
1
you reached the end!!
feeds!
log in